Nebivolol as a beta-blocker with vasodilating properties: achievements and prospects
Article Sidebar
Main Article Content
Abstract
A literature review deals with the clinical use of nebivol as a beta-blocker (BB) with vasodilating properties. The principal pharmacological properties and characteristics of the drug, its cardioselectivity and mechanisms of vasodilation are presented. The special place of nebivolol in the treatment of essential arterial hypertension (AH), coronary heart disease (CHD) and heart failure (HF) is outlined. The drug does not possess a diabetogenic activity with a long-term use, and impacts favourably on the parameters of lipid and carbohydrate metabolism. In CHD patients, nebivolol demonstrates the antianginal and antiischemic activities, and reduces the frequency of angina recurrence after coronary artery interventions. The drug is well tolerated and characterized by a high effectiveness with respect to the reduction of mortality rates in patients with chronic HF over 70 years of age, regardless of the left ventricular ejection fraction. Vasodilating BB are preferred in the treatment of CHD patients with type 2 diabetes. In case of non-obstructive coronary lesions, nebivolol is chosen among existing BBs for the treatment of microvascular angina. The use of nebivolol in AH patients, in addition to the antihypertensive effect, is characterized by a favorable impact on the function of endothelium, the metabolic profile, central hemodynamics, health-related quality of life of patients, as well as more favorable profile of side effects.
Article Details
Keywords:
References
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Muñoz D, Smith SC, Virani SS, Williams KA, Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Review. Circulation 2019;140:e596-e646. doi: https://doi.org/10.1161/CIR.0000000000000678.
Arnold S, Bratt D, Barsness G, Beatty A, Deedwania P, Inzucchi S, Kosiborod M, Lieter L, Lipska K, Newman J, Welty F, on behalf of the American Heart Association Council on Lifestyle and Cardiometabolic Health and Council on Clinical Cardiology. Clinical management of stable coronary artery disease in patients with type 2 diabetes melitus. A Scientific Statement From the American Heart Association. Circulation 2020;141:e779-e806. https://doi.org/10.1161/CIR.0000000000000678.
Bakris G, Fonseca V, Katholi R, McGill J, Messerli F, Phillips R, Raskin P, Wright J, Oakes R, Lukas M, Anderson K, Bell D. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes melitus and hypertension: a randomized controlled trail. JAMA 2004;292:2227-36. doi: https://doi.org/10.1001/jama.292.18.2227.
Bhosale V, Inamdar S, Karande V, Burute S, Murthy M, Ghatak A. Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension. J Clin Diagn Res 2014;8:Hc01-04. doi: https://doi.org/10.7860/JCDR/2014/7728.4419. Epub 2014 Jun 20.
Cannavo A, Koch W. Targeting ß3-Аdrenergic receptors in the heart: selective agonism and ß-blockade. J Cardiovasc Pharmacol 2017;69:71-8. doi:10.1097/FJC.0000000000000444.
Che Q, Schreiber M, Rafey M. Beta-blockers for hypertension: are they going out of style? Cleve Clin J Med 2009;76:533-42. doi: https://doi.org/10.3949/ccj.m.76a.09.030.
Copper-Deffoff R, Cohen J, Bakris G, Messerli F, Erdine S, Hewkin A, Kupfer S, Pepine C. Predictiors of development of diabetes mellitusin patients with coronary artery disease taking antyhypertensive medications (findings from International VErapamil SR-Trandolapril Study (INVEST). Am J Cardiol 2006;98:890-4. doi: https://doi.org/10.1016/j.amjcard.2006.04.030.
Dahlöf B, Sever P, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjieldsen S, Kristinsson A, McInnes G, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Am (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. doi: https://doi.org/10.1016/S0140-6736(05)67185-1.
De Nigris F, Mancini F, Balestrieri M, Byrns R, Fiorito C, Williams-Ignarro S, Palagiano A, Crimi E, Ignarro L, Napoli C. Therapeutic dose of nebivolol, a nitric oxide-releasing beta-blocker, reduces atherosclerosis in cholesterol – bed rabbits. Nitric Oxid 2008;14:57-64. doi: https://doi.org/10.1016/j.niox.2008.03.004.
DiFrancesco D. The role of the funny current in pacemaker activity. Circ Res 2010;106:436-46. doi: https://doi.org/10.1161/CIRCRESAHA.109.208041.
Edes J, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in eldery patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005;7:631-9. doi:10.1016/j.ejheart.2004.10.015.
Encinas J, Peiro C, Perez M, Raimundo J, Gois K, Peres M, Draghi P, Arcia C, Simões D, Murad N, Alves B, Fonseca F, Veiga G. Does nebivolol have renoprotective action in patients with chronic kidney disease conditions? An integrative review. Eur J Pharmacol 2021;905:174-80. doi: https://doi.org/10.1016/j.ejphar.2021.174180.
Ignjatovic V, Pavlovic S, Miloradovic V, Andjelkovic N, Davidovic G, Djurdjevic P, Stolic R, Iric-Cupic V, Simic I, Petrovic N, Smiljanic Z, Zdravkovic V, Simovic S, Jovanovic D, Nesic J. Influence of Different ß-Blockers on Platelet Aggregation in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy. J Cardiovasc Pharmacol Ther 2016;21:44-52. doi: https://doi.org/10.1177/1074248415581175.
Flather M, Shibata M, Coats A, Veldhuisen D, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker S, Thompson S, Poole-Wilson P. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25. doi:https://doi.org/ 10.1093/eurheartj/ehi115.
Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs 2015;75:1349-71. doi: https://doi.org/10.1007/s40265-015-0435-5.
Frishman W. Beta-adrenergic receptor blockers in hypertension: alive and weil. Prog Cardiovasc Dis 2016;59:247-52. doi: https://doi.org/10.1016/j.pcad.2016.10.005.
Galderisi M, D'Errico A. Beta-blockers and coronary flow reserve: the impotence of a vasodilatory action. Drugs 2008;68:579-90. doi: https://doi.org/10.2165/00003495-200868050-00002.
Georgescu A, Popov D, Dragan E, Dragomir E, Badila E. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension. Eur J Pharmacol 2007;10:149-58. doi: https://doi.org/10.1016/j.ejphar.2007.05.031.
Gkaliagkousi E, Gavriilaki E, Triantafyllou A, Douma S. Clinical significance of endothelial dysfunction in essential hypertension. Curr Hypertens Rep 2015;17:85. doi: https://doi.org/10.1007/s11906-015-0596-3.
Grassi G, Trevano F, Facchini A, Toutouzas T, Chanu B, Mancia G. Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: Result of adouble-blind randomized multicentre trial. Blood Press 2003;12:35-40. https://doi.org/10.1080/08038020310023271.
Gray CL, Ndefo UA. Nebivolol: a new antihypertensive agent. Am J Health Syst Pharm 2008;65:1125-1133. doi: https://doi.org/10.2146/ajhp070459.
Gulati M, Levy PD, Mukherjee D, Amsterdam E, Bhatt DL, Birtcher KK, Blankstein R, Boyd J, Bullock-Palmer RP, Conejo T, Diercks D, Gentile F, Greenwood JP, Hess EP, Hollenberg SM, Jaber WA, Jneid H, Joglar JA, Morrow DA, O'Connor RE, Ross MA, Shaw LJ. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evoluation and Diagnosis of chest pain: A Report of The American College of Cardiology/American Heart Association joint Committee on Clinical Practice Guidelines. Circulation 2021;144:e368-e454. doi: https://doi.org/10.1161/CIR.0000000000001029.
Gupta S, Wright H. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilatation by increasing nitric oxide. Cardiovasc Ther 2008;26:189-202. doi: https://doi.org/10.1111/j.1755-5922.2008.00054x.
Gur O, Gurkan S, Yumun G, Tuker P. The comparison of the effects of nebivolol and metoprolol on erectile dysfunction in the cases with coronary artery bypass surgery. Ann Thorac Cardiovasc Surg 2017;23:91-5. doi: https://doi.org/10.5761/atcs.oa.16-00242.
Kunadian V, Chieffo A, Camici P, Berry C, Escaned J, Maas A, Prescott E, Karam N, Appelman Y, Fraccaro C, Buchanan G, Manzo-Silberman S, Al-Lamee R, Regar E, Lansky A, Abbott D, Badimon L, Duncker D, Mehran R, Capodanno D, Baumbach A. 2021 An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. EuroIntervention 2021;16:1049-69. doi: https://doi.org/10.4244/EIJY20M07_01.
Lindholm L, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53. doi: https://doi.org/10.1016/S0140-6736(05)67573-3.
Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen S, Kiowski W, Mallion J, Manolis A, Narkiewicz K, Nilsson P, Olsen M, Rahn K, Redon J, Rodicio J, Ruilope L, Schmieder R, Struijker-Boudier H, Zwieten P, Viigimaa M, Zanchetti A. Reappraisal of European guidelines of hypertension management: a European society of hypertension task force document. Blood Pres 2009;18:308-47. doi: https://doi.org/10.3109/ 08037050903450468.
Mann S. Redefining beta-blocker use in hypertension: selecting the right beta-blocker and the right patient. J Am Soc Hypertens 2017;11:54-65. doi: https://doi.org/10.1016/j.jash.2016.11.007.
Michels R, Kresznai K, Makel W. Nebivolol ingibition of coronary artery smooth muscle cell proliferation after percutaneous coronary arteri intervention. Results of the NESCIO Study, a randomized, double blind trail. Eur Rev Med Pharmac Sci 2011;15:264-9. PMID:22195358.
Morgan T, Lauri J, Bertram D, Anderson A. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens 2004;17:118-23. doi: https://doi.org/10.1016/j.amjhyper.2003.09.012.
Ozyildiz A, Eroglu S, Bal U, Atar I, Okyay K, Muderrisoglu H. Effects of Carvedilol Compared to nebivolol on insulin resistance and lipid profile in patients with essential hypertension. J Cardiovasc Pharmacol Ther 2016;22:65-70. doi: https://doi.org/10.1177/1074248416644987.
Polonia J, Bartosa L, Silva J, Bertopurini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with beta-blockers either with or without vasodilator properties or with angiotensin receptor blocker. Blood Press Monnit 2010;15:235-9. doi: https://doi.org/ 10.1097/MBP.0b013e32833c8a64.
Schmidt A, Graf C, Brixius K, Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabets mellitus: the YESTONO study. Clin Drug Investig 2007;27:841-9. doi: https://doi.org/10.2165/00044011-200727120-00006.
Van Bortel L, Fici F, Mascagni F. Efficaci and tolerability of nebivolol compared with other antihypertensive drugs: metaanalysis. Am J Cardiovasc Drugs 2008;8:35-44. doi: https://doi.org/10.2165/00129784-200808010-00005.
Velasco A, Solow E, Price A, Wang Z, Arbique D, Arbique G, Adams-Huet B, Schwedhelm E, Lindner J, Vongpatanasin W. Differential effects of nebivolol vs metoprolol on microvascular function in hypertensive humans. Am J Physiol Heart Cir Physiol 2016;311:H118-H124. doi: https://doi.org/10.1152/ajpheart.00237.2016.
Wehland M, Grosse J, Simonsen U, Infanger M, Bauer J, Grimm D. The effects of newer beta-adrenoreceptor antagonists on vascular function in cardiovascular disease. Curr Vasc Pharmac 2012;10:378-90. doi: https://doi.org/10.2174/157016112799959323.
Williams B, Manсia G, Spiering W, Rosei E, Azizi M, Burnier M, Clement D, Coca A, Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip G, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 2018;39:3021-104. doi: https://doi.org/10.1093/eurheartj/ehy339.
Quang T, Rozec B, Audigane L, Dauthier C. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta. Br J Pharmacol 2009;156:601-8. doi: 10.1111/j.1476-5381.2009.00074.x.
Zhang J, Lin J, Qin X. Advances in early biomarkers of diabetic nephropathy. Rev Assos Med Bras 2018;64:85-92. doi: https://doi.org/10.1590/1806-9282.6401.85.
Zhano Y, Vanhoutte P, Leung S. Vascular nitric oxide: Beyond Enos. J Pharmacol Sci 2015;120:83-94. doi: https://doi.org/10.1016/j.jphs.2015.09.002.